NORTH CHICAGO, Ill., Nov. 3, 2015 /PRNewswire/ -- AbbVie (NYSE: ABBV), a global biopharmaceutical company, today announced that data on HUMIRA® (adalimumab), investigational medicines and the overall impact of rheumatologic diseases from more than 40 abstracts, including three oral presentations, will be presented at the 2015 American College of Rheumatology (ACR) Annual Meeting, Nov. 7-11, in San Francisco. These data reinforce AbbVie's continued leadership in immunology and commitment to those living with a variety of inflammatory diseases.
"As a leader in delivering medicines to address unmet needs in immune-mediated disorders, we are highlighting scientific insights at ACR from our immunology portfolio, including data showcasing ongoing research with HUMIRA and the significant role anti-TNF therapies have played in the management of rheumatologic diseases1-2," said Scott Brun, M.D., vice president, pharmaceutical development, AbbVie. "We also continue to drive innovation within our pipeline, looking at multiple scientific approaches and novel solutions to help improve patient care across a variety of autoimmune diseases with unmet needs."
HUMIRA abstracts to be presented include results from a Phase 3 trial evaluating the efficacy and safety of HUMIRA as an investigational treatment for non-infectious, intermediate, posterior, or panuveitis; and data on the investigational treatment of adult patients with polyarticular juvenile idiopathic arthritis. Additionally, multiple abstracts being presented include data highlighting the importance and ongoing evaluation of established tumor necrosis factor (TNF)-alpha inhibitors in several rheumatologic diseases, including rheumatoid arthritis, ankylosing spondylitis and psoriatic arthritis.
Since first gaining approval 12 years ago, HUMIRA has been approved in more than 87 countries. It is currently being used to treat more than 940,000 patients worldwide across 13 globally approved indications. HUMIRA is one of the most comprehensively studied biologics available and is distinguished by 18 years of clinical trial experience in immunology beginning with rheumatoid arthritis.
AbbVie will also present 10 abstracts on investigational medicines aiming to advance the development of novel molecules to create solutions for patients who need it most. Data will spotlight ABT-122 and ABT-981, two unique dual variable domain immunoglobulins (DVD-Ig™) under investigation to treat certain immunologic and inflammatory disorders by blocking both TNF and IL-17, and IL-1α and IL-1β, respectively. Additionally, late-breaking data on ABT-494, an investigational selective JAK1 inhibitor, will be presented at the meeting. AbbVie announced in September of this year that it will advance ABT-494 to Phase 3 studies in rheumatoid arthritis.
Abstracts of Interest
HUMIRA (AbbVie-sponsored) Abstracts
Rheumatoid Arthritis
Uveitis
Psoriatic Arthritis
Juvenile Idiopathic Arthritis
Ankylosing Spondylitis
Investigational Medicines Abstracts
Rheumatoid Arthritis
Systemic Lupus Erythematosus
Osteoarthritis
About HUMIRA in the U.S.
Uses3
HUMIRA is a prescription medicine used:
Important Safety Information3
HUMIRA is a TNF blocker medicine that affects the immune system and can lower the body's ability to fight infections. Serious infections have happened in people taking HUMIRA. These serious infections include tuberculosis (TB) and infections caused by viruses, fungi, or bacteria that have spread throughout the body. Some people have died from these infections. People should be tested for TB before HUMIRA use and monitored for signs and symptoms of TB during therapy. People at risk of TB may be treated with medicine for TB. Treatment with HUMIRA should not be started in a person with an active infection, unless approved by a doctor. HUMIRA should be stopped if a person develops a serious infection. People should tell their doctor if they live in or have been to a region where certain fungal infections are common, have had TB or hepatitis B, are prone to infections, or have symptoms such as fever, fatigue, cough, or sores.
For people taking TNF blockers, including HUMIRA, the chance of getting lymphoma or other cancers may increase. Some people have developed a rare type of cancer called hepatosplenic T-cell lymphoma. This type of cancer often results in death. If using TNF blockers, including HUMIRA, the chance of getting two types of skin cancer (basal cell and squamous cell) may increase. These types are generally not life-threatening if treated.
Other possible serious side effects with HUMIRA include hepatitis B infection in carriers of the virus; allergic reactions; nervous system problems; blood problems; certain immune reactions, including a lupus-like syndrome; liver problems; and new or worsening heart failure or psoriasis. The use of HUMIRA with anakinra or abatacept is not recommended. People using HUMIRA should not receive live vaccines.
Common side effects of HUMIRA include injection site reactions (redness, rash, swelling, itching, or bruising), upper respiratory infections (including sinus infections), headaches, rash, and nausea.
HUMIRA is given by injection under the skin.
The benefits and risks of HUMIRA should be carefully considered before starting therapy.
Please click here for the Full Prescribing Information and Medication Guide.
About AbbVie
AbbVie is a global, research-based biopharmaceutical company formed in 2013 following separation from Abbott Laboratories. The company's mission is to use its expertise, dedicated people and unique approach to innovation to develop and market advanced therapies that address some of the world's most complex and serious diseases. Together with its wholly-owned subsidiary, Pharmacyclics, AbbVie employs more than 28,000 people worldwide and markets medicines in more than 170 countries. For further information on the company and its people, portfolio and commitments, please visit www.abbvie.com. Follow @abbvie on Twitter or view careers on our Facebook or LinkedIn page.
Forward-Looking Statements
Some statements in this news release may be forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995. The words "believe," "expect," "anticipate," "project" and similar expressions, among others, generally identify forward-looking statements. AbbVie cautions that these forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those indicated in the forward-looking statements. Such risks and uncertainties include, but are not limited to, challenges to intellectual property, competition from other products, difficulties inherent in the research and development process, adverse litigation or government action, and changes to laws and regulations applicable to our industry.
Additional information about the economic, competitive, governmental, technological and other factors that may affect AbbVie's operations is set forth in Item 1A, "Risk Factors," in AbbVie's 2014 Annual Report on Form 10-K, which has been filed with the Securities and Exchange Commission. AbbVie undertakes no obligation to release publicly any revisions to forward-looking statements as a result of subsequent events or developments, except as required by law.
References
SOURCE AbbVie
YOU ARE ABOUT TO LEAVE FOR A 3RD PARTY WEBSITE
Notice
The "Yes" link below will take you out of the AbbVie family of websites.
Links which take you out of the AbbVie worldwide websites are not under the control of AbbVie, and AbbVie is not responsible for the contents of any such site or any further links from such site. AbbVie is providing these links to you only as a convenience and the inclusion of any link does not imply endorsement of the linked site by AbbVie.
The Internet site that you have requested may not be optimized to your screen size.
Do you wish to leave this site?